icad inc Overview
Industry: Medical Devices
Sector: Healthcare
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company's breast AI suite includes cancer detection, automated density assessment, and breast cancer risk assessment solutions for both 2D and 3D mammography. It offers PowerLook, a back-end architecture platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and PowerLook Density Assessment provides automated, consistent, and standardized breast density assessments. The company also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a clinical decision support tool that provides breast cancer risk estimation based on a screening mammogram; and VeraLook, a solution designed to support detection of colonic polyps in conjunction with Computed Tomography Colonography. In addition, it offers Xoft Axxent electronic brachytherapy systems for the treatment of early-stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire. iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company's breast AI suite includes cancer detection, automated density assessment, and breast cancer risk assessment solution Read Moreicad inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.
icad inc
Score
Recent News
Earnings Per Share
Score 2.00/5
icad inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Medical Devices industry
, Abbott Laboratories
, DexCom Inc
, Edwards Lifesciences Corp
are companies with high ratings.
Return on Equity
Score 1.60/5
icad inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
In
Medical Devices industry
, Abbott Laboratories
, DexCom Inc
, Edwards Lifesciences Corp
are companies with high ratings.
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
ROE
Company 0%
SP500 Industry 0%
Net Margin
Score 1.60/5
icad inc
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
In
Medical Devices industry
, Abbott Laboratories
, DexCom Inc
, Edwards Lifesciences Corp
are companies with high ratings.
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
0%
10.0%
20.0%
30.0%
40.0%
Net Margin
Company 0%
SP500 Industry 0%
Leverage
Score 3.20/5
icad inc
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
In
Medical Devices industry
, Abbott Laboratories
, DexCom Inc
, Edwards Lifesciences Corp
are companies with high ratings.
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
0
10.0
20.0
30.0
40.0
Leverage
Company 0
SP500 Industry 0
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios
